These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30828393)

  • 21. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
    Langbein T; Weber WA; Eiber M
    J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Requisites for successful theranostics with radionuclide-based reporter gene imaging.
    Ahn BC
    J Drug Target; 2014 May; 22(4):295-303. PubMed ID: 24417717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive palliative care program at a tertiary cancer center in Jordan.
    Shamieh O; Hui D
    Am J Hosp Palliat Care; 2015 Mar; 32(2):238-42. PubMed ID: 24259403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Six country vignettes: Strengthening radiotherapy and theranostics.
    Mikhail-Lette M; Cordero L; Lievens Y; Al-Ibraheem A; Urbain JL; Chera B; Muylle K; Vaandering A; Rosa AA; Cerci JJ; Sathekge M; Minjgee M; Nansalmaa E; Erdenechimeg S; Ruiz RL; Scott A; Paez D; Giammarile F; Veduta A; Minoshima E; Vichare S; Abdel-Wahab M
    J Cancer Policy; 2024 Jun; 40():100471. PubMed ID: 38556128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer.
    Kasi PM; Sharma A; Jain MK
    Case Rep Oncol; 2019; 12(1):98-103. PubMed ID: 31043945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
    Zhang J; Singh A; Kulkarni HR; Schuchardt C; Müller D; Wester HJ; Maina T; Rösch F; van der Meulen NP; Müller C; Mäcke H; Baum RP
    Semin Nucl Med; 2019 Sep; 49(5):422-437. PubMed ID: 31470935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Status and Growth of Nuclear Theranostics in Singapore.
    Huang HL; Tong AKT; Thang SP; Yan SX; Lam WWC; Loke KSH; Tang CYL; Cheng LTJ; Ooi GSK; Low HC; Magsombol BM; Tham WY; Goh CXY; Tan CJ; Khor YM; Zaheer S; Bharadwaj P; Xie W; Ng DCE
    Nucl Med Mol Imaging; 2019 Apr; 53(2):96-101. PubMed ID: 31057680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
    Ferdinandus J; Violet J; Sandhu S; Hofman MS
    Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
    Eberlein U; Cremonesi M; Lassmann M
    J Nucl Med; 2017 Sep; 58(Suppl 2):97S-103S. PubMed ID: 28864620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.
    Hörsch D; Kulkarni HR; Baum RP
    Ann Transl Med; 2014 Jan; 2(1):1. PubMed ID: 25332977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Jordan palliative care initiative: a WHO Demonstration Project.
    Stjernswärd J; Ferris FD; Khleif SN; Jamous W; Treish IM; Milhem M; Bushnaq M; Al Khateib A; Al Shtiat MN; Wheeler MS; Alwan A
    J Pain Symptom Manage; 2007 May; 33(5):628-33. PubMed ID: 17482059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology].
    Schaefer N; Prior J
    Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exciting Opportunities in Nuclear Medicine Imaging and Therapy.
    Lapa C
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31718092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
    Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
    Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
    Lenzo NP; Meyrick D; Turner JH
    Diagnostics (Basel); 2018 Feb; 8(1):. PubMed ID: 29439481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.
    Solnes LB; Werner RA; Jones KM; Sadaghiani MS; Bailey CR; Lapa C; Pomper MG; Rowe SP
    J Nucl Med; 2020 Mar; 61(3):311-318. PubMed ID: 31924727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine.
    Levine R; Krenning EP
    J Nucl Med; 2017 Sep; 58(Suppl 2):3S-9S. PubMed ID: 28864612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Theranostics: A treasured tailor for tomorrow.
    Jeelani S; Reddy RC; Maheswaran T; Asokan GS; Dany A; Anand B
    J Pharm Bioallied Sci; 2014 Jul; 6(Suppl 1):S6-8. PubMed ID: 25210387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer.
    Velikyan I
    Pharmaceuticals (Basel); 2020 Mar; 13(3):. PubMed ID: 32151049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. General Concepts in Theranostics.
    Nunes RF; Zuppani RMF; Coutinho AM; Barbosa FG; Sapienza MT; Marin JFG; Buchpiguel CA
    PET Clin; 2021 Jul; 16(3):313-326. PubMed ID: 34053576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.